Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New method to visualize small-molecule interactions inside cells

Like people in a large company, proteins in cells constantly interact with each other to perform various jobs. To develop new disease therapies, researchers are trying to control these interactions with small-molecule drugs that cause specific proteins to associate more or less with their "coworkers."

13 Dec 2018

New technology for profiling genetic makeup of myeloma tumor cells developed

Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells - outlining how cancer cells hijack specific pathways for uncontrolled proliferation - will lead to more efficient ways to fight it.

7 Dec 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Multiple myeloma is the second most common type of blood cancer where cancer cells accumulate in the bone marrow, crowding out healthy blood cells.

1 Nov 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology, published online an analysis of patient samples from the Intergroupe Francophone du Myéloma 2009 trial.

1 Oct 2018

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Today the U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing-based test for minimal residual disease in patients with acute lymphoblastic leukemiaor multiple myeloma. MRD is a measure of the amount of cancer cells remaining in a person's bone marrow.

30 Sep 2018

Clinical trial investigators found non-compliant with requirement to report results on EU register

According to EU legislation, clinical trials must be prospectively registered in the European Union Clinical Trials Register and the main results must be reported there one year after completion of the trial. This information is thus publicly available.

25 Sep 2018

New guidance for treatment of bone loss in hematologic stem cell transplant Recipients

Hematopoietic stem cell transplantation is the treatment of choice for many patients with malignant and non-malignant hematological diseases, such as leukemia and multiple myeloma. The success of recent advances in such transplantation techniques and supportive care measures, has led to greater numbers of long-term HSCT survivors.

20 Sep 2018

Study gives new insights into how cells leverage GPCRs to control inflammation

G-protein-coupled receptors are everywhere in our bodies. They are embedded in our cell membranes, where they act as signal transducers, allowing cells to respond to their external environments.

19 Sep 2018

New system accelerates discovery of chemical compounds that inhibit enzyme implicated in cancers

Researchers at the National Center for Advancing Translational Sciences, part of the National Institutes of Health, have developed a system to accelerate the discovery of chemical compounds that inhibit an enzyme implicated in a number of cancers.

6 Sep 2018

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.

31 Aug 2018

Study yields therapeutic clues to combat drug resistance in rare aggressive cancer

Stephen Elledge, PhD, and his team did not set out to find therapies that could render tumors less resistant to therapy or make existing drugs more potent against a rare form of cancer. But these are precisely the clinical insights that their most recent study has yielded.

29 Aug 2018

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

To further advance the study and treatment of blood cancers, Perlmutter Cancer Center at NYU Langone Health has significantly expanded its Blood and Marrow Transplant Program.

20 Aug 2018

NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients

A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug combination for a patient quickly.

13 Aug 2018

New discovery could pave way for improved leukemia treatment

Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About one-third of leukemia patients possess this favorable mutation, but until now, how it helps improve outcomes has remained unknown.

9 Aug 2018

RNA and DNA sequencing platform matches broader swath of drugs to late-stage cancer patients

A comprehensive RNA and DNA sequencing platform benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them, according to results from a clinical trial published in JCO Precision Oncology in August.

9 Aug 2018

Scientists solve 60-year-old mystery of how thalidomide caused birth defects

More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?

2 Aug 2018

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New method to visualize small-molecule interactions inside cells

New technology for profiling genetic makeup of myeloma tumor cells developed

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Clinical trial investigators found non-compliant with requirement to report results on EU register

New guidance for treatment of bone loss in hematologic stem cell transplant Recipients

Study gives new insights into how cells leverage GPCRs to control inflammation

New system accelerates discovery of chemical compounds that inhibit enzyme implicated in cancers

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Study yields therapeutic clues to combat drug resistance in rare aggressive cancer

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients

New discovery could pave way for improved leukemia treatment

RNA and DNA sequencing platform matches broader swath of drugs to late-stage cancer patients

Scientists solve 60-year-old mystery of how thalidomide caused birth defects

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in